The Medicines Company (NASDAQ:MDCO) Expected to Post Earnings of -$0.66 Per Share

Equities analysts expect that The Medicines Company (NASDAQ:MDCO) will announce ($0.66) earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for The Medicines’ earnings. The highest EPS estimate is ($0.62) and the lowest is ($0.68). The Medicines reported earnings of ($0.63) per share in the same quarter last year, which suggests a negative year over year growth rate of 4.8%. The firm is scheduled to issue its next earnings results on Wednesday, August 7th.

According to Zacks, analysts expect that The Medicines will report full year earnings of ($2.51) per share for the current fiscal year, with EPS estimates ranging from ($2.59) to ($2.40). For the next fiscal year, analysts expect that the company will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.80) to ($1.68). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for The Medicines.

The Medicines (NASDAQ:MDCO) last announced its earnings results on Thursday, April 25th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.09). During the same quarter last year, the firm earned ($0.76) EPS. The Medicines’s revenue was down 100.0% compared to the same quarter last year.

A number of brokerages have recently commented on MDCO. Robert W. Baird began coverage on shares of The Medicines in a report on Wednesday, March 27th. They issued an “outperform” rating and a $80.00 target price for the company. Zacks Investment Research cut shares of The Medicines from a “hold” rating to a “sell” rating in a report on Thursday, May 23rd. BidaskClub raised shares of The Medicines from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Roth Capital started coverage on shares of The Medicines in a report on Thursday, March 21st. They set a “buy” rating and a $75.00 price target for the company. Finally, Chardan Capital reissued a “buy” rating and set a $90.00 price target (up from $85.00) on shares of The Medicines in a report on Friday, April 26th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $63.78.

In other news, Director Alexander J. Denner purchased 160,000 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The stock was purchased at an average cost of $34.50 per share, with a total value of $5,520,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alexander J. Denner purchased 85,000 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The shares were purchased at an average cost of $34.83 per share, with a total value of $2,960,550.00. The disclosure for this purchase can be found here. Insiders have purchased 676,000 shares of company stock valued at $23,087,140 over the last three months. 10.29% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of Montreal Can grew its position in The Medicines by 13.3% during the first quarter. Bank of Montreal Can now owns 3,556 shares of the company’s stock worth $99,000 after buying an additional 417 shares during the period. Oregon Public Employees Retirement Fund grew its position in The Medicines by 1.8% during the first quarter. Oregon Public Employees Retirement Fund now owns 25,460 shares of the company’s stock worth $712,000 after buying an additional 460 shares during the period. Piedmont Investment Advisors Inc. grew its position in The Medicines by 3.4% during the fourth quarter. Piedmont Investment Advisors Inc. now owns 15,698 shares of the company’s stock worth $300,000 after buying an additional 517 shares during the period. Mason Street Advisors LLC grew its position in The Medicines by 3.4% during the first quarter. Mason Street Advisors LLC now owns 21,112 shares of the company’s stock worth $590,000 after buying an additional 697 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in The Medicines by 11.1% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,767 shares of the company’s stock worth $217,000 after buying an additional 777 shares during the period.

Shares of NASDAQ:MDCO traded down $1.66 on Tuesday, reaching $33.70. The company’s stock had a trading volume of 124,519 shares, compared to its average volume of 1,582,703. The business has a 50-day moving average price of $34.61. The Medicines has a 52-week low of $16.69 and a 52-week high of $41.57. The company has a market cap of $2.69 billion, a PE ratio of -11.62 and a beta of 1.13.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels.

Recommended Story: Market Perform

Get a free copy of the Zacks research report on The Medicines (MDCO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.